Status
Conditions
Treatments
About
To determine whether using DNA methylome to select embryos can increase the live birth rate.
Full description
The rationale for the study is to establish the risk/benefit ratio of PIMS in women with in vitro fertilization (IVF) treatment, as DNA methylome is a potential biomarker in blastocyst selection in assited reproductive technology (ART). DNA methylation plays an important role during embryogenesis, global abnormal methylome reprogramming often occurs in human embryos, and DNA methylome pattern is associated with live birth rate. However, there is still no technology using DNA methylome as an indicator in preimplantation embryo screening. Recent paper reported that using Pre-implantation Methylome Screening (PIMS) can select embryos with better methylation state and euploid chromosomes. The efficiency of PIMS needs further validation through randomized clinical trial.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
b) Women who obtain 2 or more good-quality blastocysts that defined as morphological score of inner cell mass B or A, trophectoderm C or better, and grade 4 or better on Day 5 of embryo culture.
Exclusion criteria
4.2 Exclusion Criteria
Primary purpose
Allocation
Interventional model
Masking
1,146 participants in 2 patient groups
Loading...
Central trial contact
Yuan Gao, Professor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal